NEW YORK (GenomeWeb) – Danaher today said that its first quarter sales grew 5 percent year over year, while its Life Science & Diagnostics segment grew 2 percent. 

For the three months ended April 3, the Washington-based conglomerate posted sales of $4.87 billion, up from $4.66 billion in the year-ago quarter, and beating the consensus Wall Street estimate of $4.83 billion. 

Core sales improved 5 percent year over year, while acquisitions added 6 percentage points to growth. Currency effects dampened results by 6.5 percent, the firm said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.